Search

Your search keyword '"Alan B. Rickinson"' showing total 261 results

Search Constraints

Start Over You searched for: Author "Alan B. Rickinson" Remove constraint Author: "Alan B. Rickinson"
261 results on '"Alan B. Rickinson"'

Search Results

1. Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

2. Data from A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

3. Supplementary Methods, Figures 1 - 2, Tables 1 - 3 from Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients

4. Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.

5. Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs.

6. Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.

7. Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children.

8. Epstein–Barr virus

9. Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.

10. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.

11. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.

12. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

13. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

14. Transient reduction in IgA(+) and IgG(+) memory B cell numbers in young EBV-seropositive children: the Generation R Study

15. EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins

16. The Global Landscape of EBV-Associated Tumors

17. Proteome-wide analysis of CD8+ T cell responses to EBV lytic infection

18. Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction

19. The Immunology of Epstein-Barr Virus–Induced Disease

20. The Epstein-Barr Virus BamHI C Promoter Is Not Essential for B Cell Immortalization In Vitro , but It Greatly Enhances B Cell Growth Transformation

21. Epstein-Barr virus-associated lymphomas

22. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases

23. A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

24. Cellular immune controls over Epstein–Barr virus infection: new lessons from the clinic and the laboratory

25. MHC II tetramers visualize human CD4+ T cell responses to Epstein–Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response

26. Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs

27. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation

28. Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules

29. Transient reduction in IgA

30. Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination

31. Immunity to Oncogenic Viruses

32. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus

33. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction

34. Epstein-Barr Virus BamHI W Repeat Number Limits EBNA2/EBNA-LP Coexpression in Newly Infected B Cells and the Efficiency of B-Cell Transformation: a Rationale for the Multiple W Repeats in Wild-Type Virus Strains

35. The role of tetraspanin CD63 in antigen presentation via MHC class II

36. Epstein–Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family

37. Immune defence against EBV and EBV-associated disease

38. A novel latent membrane 2 transcript expressed in Epstein-Barr virus–positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

39. Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology

40. Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence

41. Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen Presentation

42. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells

43. The Effects of Acute Malaria on Epstein-Barr Virus (EBV) Load and EBV-Specific T Cell Immunity in Gambian Children

44. EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines

45. Cancer Virus : The Discovery of the Epstein-Barr Virus

46. CD4 and CD8 T cell responses to tumour-associated Epstein–Barr virus antigens in nasopharyngeal carcinoma patients

47. Epstein-Barr Virus Exploits BSAP/Pax5 To Achieve the B-Cell Specificity of Its Growth-Transforming Program

48. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates

49. Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection

50. Primary immunodeficiencies and the control of Epstein-Barr virus infection

Catalog

Books, media, physical & digital resources